Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | PRKCG | P05129 | 1/20 | 0.70 |
| ▸ | PRKACA | P17612 | 1/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | AKT1 | P31749 | 1/20 | 0.70 |
| ▸ | GSK3A | P49840 | 1/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.70 |
| ▸ | PRKX | P51817 | 1/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.70 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.70 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.70 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.70 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082503 | 0.97 | ROCK2 (0.74) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL14082493 | 0.92 | MMP13 (0.79) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL14082585 | 0.90 | ALDH1A1 (0.69) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL2984197 | 0.90 | NAMPT (0.72) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL14082589 | 0.87 | RAB9A (0.61) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL14082489 | 0.87 | ALDH1A1 (0.61) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL539269 | 0.85 | MMP13 (1.00) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL2570995 | 0.85 | LMNA (0.62) | MMP13NAMPTMKNK1MKNK2LMNA | |
| SCHEMBL248761 | 0.85 | MAPK1 (0.68) | MMP13ROCK2RPS6KA5MAP4K4PRKCG | |
| SCHEMBL14082553 | 0.85 | WDR5 (0.64) | MMP13ROCK2RPS6KA5MAP4K4PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| CN-102958917-B | Compositions and methods for modulating the wnt signaling pathway | IRM LLC (BM) | 2014-10-08 | — | — | CN | disclosed |
| EP-2588453-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2013-05-08 | — | — | EP | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| CN-102958917-A | Compositions and methods for modulating the wnt signaling pathway | IRM LLC | 2013-03-06 | — | — | CN | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | MMP13 1866/4885ROCK2 159/4885RPS6KA5 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.